Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study the differential gene expression in A375 cells treated with DMSO or XL413 or OF1 or OF1 and XL413 combination.

ABSTRACT: Study the differential gene expression in A375 cells treated with DMSO or XL413 or OF1 or OF1 and XL413 combination.

PROVIDER: PRJNA771637 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16355088_1.fastq.gz	Fastqsanger.gz
	SRR16355088_2.fastq.gz	Fastqsanger.gz
	SRR16355089_1.fastq.gz	Fastqsanger.gz
	SRR16355089_2.fastq.gz	Fastqsanger.gz
	SRR16355090_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Study the differential gene expression in A375 cells treated with DMSO or XL413 or GSK343 or GSK343 and XL413 combination

Project description:The study evaluated the differential gene expression in A375 cells treated with DMSO when compared to XL413 or GSK343 or GSK343 and XL413 combination using RNA-seq

2022-08-10 | GSE186276 | GEO

Study the differential gene expression in A375 cells treated with DMSO or XL413 or OF1 or OF1 and XL413 combination.

Project description:The study evaluated the differential gene expression in A375 cells treated with DMSO when compared to XL413 or OF1 or OF1 and XL413 combination using RNA-seq

2022-08-10 | GSE185976 | GEO

Study the differential gene expression in A375 cells treated with DMSO or XL413 or GSK343 or GSK343 and XL413 combination

Project description:Study the differential gene expression in A375 cells treated with DMSO or XL413 or GSK343 or GSK343 and XL413 combination

| PRJNA773103 | ENA

Gene expression changes caused by treatment of A375 cells with A-366 versus DMSO (vehicle)

Project description:We use RNAseq to examine gene expression changes in A375 cells after treatment with A-366 versus DMSO (vehicle) of mScarlet tagged H3.3(wildtype) vs. H3.3(K9M)

2022-01-02 | GSE192612 | GEO

Human A375 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59340 | GEO

Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines

Project description:Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA was used as template for cDNA synthesis.

2015-12-02 | GSE52882 | GEO

Human A375 melanoma cell line treated with trifluorothymidine (TFT) and lactimidomycin (LTM)

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59183 | GEO

Analysis of A375 and A375 clones that acquired resistance to GSK2118436 after treatment with GSK2118436 (GSK436), GSK1120212 (GSK212), or the combination of GSK2118436 and GSK1120212 for 24 hour

Project description:In an effort to understand the mechanisms of acquired resistance to BRAF inhibitors, we isolated clones that acquired resistance to the BRAF inhibitor GSK2118436 derived from the A375 BRAF V600E mutant melanoma cell line. This resistance clones acquired mutations in NRAS and MEK1. One clones, 16R6-4, acquired two mutations in NRAS – Q61K and A146T. Proliferation and western blot analyses demonstrated that these clones were insensitive to single agent GSK2118436 or GSK1120212 (an allosteric MEK inhibitor) but were sensitive to the combination of GSK2118436 and GSK1120212. To further characterize this combination, global transcriptomic analysis was performed in A375 and 16R6-4 after 24 hour treatment with GSK2118436, GSK1120212 or the combination of GSK2118436 and GSK1120212. This data set was published in Molecular Cancer Therapeutics with the title “Combined inhibition of BRAF and MEK, BRAF and PI3K/mTOR, or MEK and PI3K/mTOR overcomes acquired resistance to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutations” by Greger, J.G., et.al. A375 and 16R6-4 (an A375 derived GSK2118436 resistance clone) were treated for 24 hours with 0.1 micromolar GSK2118436, 1 micromolar GSK2118436, 0.01 micromolar GSK1120212, 0.1 micromolar GSK2118436 + 0.01 micromolar GSK1120212, or 1 micromolar GSK2118436 + 0.01 micromolar GSK1120212.

2012-02-01 | E-GEOD-35230 | biostudies-arrayexpress

Expression data of A375 melanoma cells after DMSO or MLN4924 +/- Nutlin treatment for 26 hours

Project description:Microarrays were used to determine the change in gene expression of genes involved in the p53 pathway after siRNA knock down of p53, CDT1 or BRCA1 A375 cells were grown, transfected with siRNA, incubated for 48hrs, then incubated for another 26hrs in the presence of either 0.065% DMSO as control, 650nM MLN4924, 5uM Nutlin or 100nM Daunorubicin. RNA extraction and hybridization on Affymetrix HG-U133Plus 2.0 arrays were performed.

2012-07-04 | GSE39091 | GEO

RNA-seq of human melanoma cell line A375 treated with the tetracycline analogs Col-3 or doxycycline against untreated controls

Project description:Apart from their antibacterial activity, tetracyclines have demonstrated diverse and beneficial “off-target” biological activities in human disease, spurring interest in their development as non-antimicrobial therapeutics in diseases such as cancer. To better define biological pathways modified by the tetracyclines in human cancer, we sought to determine differential gene expression in the A375 cancer cell line treated with the tetracyclines, Col-3 and doxycycline, relative to control (vehicle-treated) cells. A375 cells were treated with either 10 μM Col-3, 10 μM doxycycline, or vehicle (DMSO) for 6 h, and changes to gene expression were assessed by RNA-Seq.

2018-09-01 | E-MTAB-7126 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data